The possibilities of phytotherapy in the treatment of patients with functional disorders of the digestive tract

Cover Page

Cite item

Full Text

Abstract

In recent years there has been an increase in the number of patients with functional diseases of the gastrointestinal tract, and often there is a combination of various variants of functional disorders, as well as their combination with other diseases of the gastrointestinal tract. In this regard, there is a need to find new effective approaches in the treatment of this group of patients, which will help to avoid the simultaneous administration of several medicines. One of these therapeutic approaches is the appointment of a combined herbal preparation STW 5 (Iberogast®), which affects various pathogenetic mechanisms of functional disorders. The components included in the formulation have a synergistic effect, potentiating the actions of each other. In patients with functional disorders, the drug can be used both in the form of monotherapy, and the composition of complex treatment. The efficacy and safety of STW 5 in the treatment of functional disorders of the digestive tract has been demonstrated in a large number of clinical studies and corresponds to a level of evidence of IA.

About the authors

I. G Bakulin

I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation

Email: igbakulin@yandex.ru
д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии ФГБОУ ВО «СЗГМУ им. И.И.Мечникова» 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

E. V Skazyvaeva

I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation

Email: skazyvaeva@yandex.ru
канд. мед. наук, доц. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии ФГБОУ ВО «СЗГМУ им. И.И.Мечникова» 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

E. B Avalueva

I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation

Email: avalueva@mail.ru
д-р мед. наук, проф. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии ФГБОУ ВО «СЗГМУ им. И.И.Мечникова» 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

M. I Skalinskaya

I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation

Email: mskalinskaya@yahoo.com
канд. мед. наук, доц. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии ФГБОУ ВО «СЗГМУ им. И.И.Мечникова» 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

I. A Oganezova

I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation

Email: oganezova@rambler.ru
д-р мед. наук, проф. каф. пропедевтики внутренних болезней, гастроэнтерологии и диетологии ФГБОУ ВО «СЗГМУ им. И.И.Мечникова» 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41

References

  1. Drossman D.A, Hasler W.L. Rome IV - Functional GI disorders: disorders of gut - brain interaction. Gastroenterology 2016; 150 (6): 1257-61.
  2. Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Черемушкина Н.В. Синдром раздраженного кишечника. Римские критерии IV // Consilium Medicum. 2016; 18 (8): 79-85.
  3. Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology 2016; 150: 1262-79.
  4. Jones M.P, Dilley J.B, Drossman D et al. Brain - gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil 2006; 18: 91-103.
  5. Шептулин А.А., Курбатова А.А. Новые Римские критерии функциональной диспепсии IV пересмотра. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (4): 124-8.
  6. Mitchell C.M, Drossman D.A. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92: 1282-4.
  7. Ottillinger B et al. STW 5 (Iberogast®) - a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65-72.
  8. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995; 109: 671-80.
  9. Keohane J. Functional Dyspepsia and Nonerosive Reflux Disease: Clinical Interactions and Their Implications. Med Gen Med 2007; 9 (3): 31.
  10. Oustamanolakis P, Tack J. Dyspepsia: organic versus functional. J Clin Gastroenterol 2012; 46 (3): 175-90.
  11. Young Wook Noh M.D, Hye-Kyung Jung M.D, Seong-Eun Kim M.D, Sung-Ae Jung M.D. Overlap of Erosive and Non - erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria. J Neurogastroenterol Motil 2010; 16 (2). doi: 10.5056/jnm.2010.16.2.148
  12. Калинин А.В., Логинов А.В., Хазанов А.И. Гастроэнтерология и гепатология: диагностика и лечение. Руководство для врачей. М.: МЕДпресс - информ, 2013 г.
  13. Авалуева Е.Б., Ткаченко Е.И., Сказываева Е.В. и др. Использование препаратов висмута в лечении синдрома раздраженного кишечника. Гастроэнтерология Санкт - Петербурга. 2013; 3-4: 11-4.
  14. Белоусова Л.Н., Пахомова И.Г. Синдром раздраженного кишечника. Новые возможности фармакопротекции РМЖ. Мед. обозрение. Клинические рекомендации и алгоритмы для практикующих врачей. Гастроэнтерология. 2014; 31: 2222-6.
  15. Itokawa H, Morris-Natschke S.L, Akiyama T, Lee K.H. Plant - derived natural product research aimed at new drug discovery. Nat Med 2008; 62: 263-80.
  16. Njuguna N.M, Masimirembwa C, Chibale K. Identification and characterization of reactive metabolites in natural products - driven drug discovery. Nat Prod 2012; 75: 507-13.
  17. Vinson B. Development of Iberogast®: clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F, editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert, 2009; p. 167-89.
  18. Мазнев Н.И. Энциклопедия лекарственных средств. 3-е изд., испр. и доп. М., 2004.
  19. Heinle H, Hagelauer D, Pascht U et al. Intestinal spasmolytic effects of STW 5 (Iberogast®) and its components. Phytomedicine 2006; 13: SV 75-9.
  20. Ammon H.P, Kelber O, Okpanyi S.N. Spasmolytic and tonic effect of STW 5 (Iberogast) in intestinal smooth muscle. Phytomedicine 2006; 13: SV 67-74.
  21. Liu C.Y, Müller M.H, Glatzle J et al. The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 759-64.
  22. Simmen U, Kelber O, Okpanyi S.N et al. Bimding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 2006; 13: 51-5.
  23. Khayyal M.T, Seif-El-Nasr M, El-Ghazaly M.A et al. Mechanisms involved in the gastro - protective effect of STW 5 (Iberogast) and its components against ulcers and rebound activity. Phytomedicine 2006; 13: SV 56-66.
  24. Khayyal M.T, El-Ghazaly M.A, Kenawy S.А et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittel Forsch/Drug Res 2001; 51: 545-53.
  25. Schempp H, Totha A, Weiser D, Elstnera E. Antioxidative Properties of Iberis amara Extracts in Biochemical Model Reactions. Arzneim - Forsch/Drug Res 2003; 53 (8): 568-77.
  26. Germann I et al. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast®). Phytomedicine 2006; 13: 143-9.
  27. Michael S, Kelber O, Vinson B, Nieber K. Herbal preparations STW 5 and STW 6 inhibit inflammation - mediated motility disorders in the ileum. Gut 2006; 55: SV A206.
  28. Abdel-Aziz H, Wadie W, Kelber O et al. Anti inflammatory effect of STW5 in colonic inflammation in vivo. Gut 2007; 56: A154.
  29. Schempp H, Weiser D, Kelber O, Elstner E.F. Radical scavenging and anti infl ammatory properties of STW 5 and its components. Phytomedicine 2006; 13: SV 36-44.
  30. Kruger D, Zeller F, Kellber O et al. The phytopharmacon STW 5 (Iberogast) has pro - secretory effects of the human small and large intestine. Gut 2007; 55 (Suppl. V): A94.
  31. Ritter R et al. Clinical trial on standardised celandine extract in patients with functional epigastric complaints: results of a placebo - controlled double - blind trial. Complement Ther Med 1993; 1: 189-93.
  32. Harries N et al. Antifoaming and carminativeaction of volatile oils. J Clin Pharmacy 1978; 2: 171-7.
  33. Krüger D, Gruber L, Angay O et al. Efficacy profile of STW 5 (Iberogast) offers new options for treatment of gastrointestinal diseases. Z Phytother 2008; 29: S29.
  34. Schemann M, Michel K, Hohenester B, Rühl A. Region specific effects of STW 5 and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13: SV 90-9.
  35. Pilichiewicz A.N, Horowitz M, Russo A et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal (APD) motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102: 1-8.
  36. Vinson B.R, Holtmann G. Onset of action and efficiency of STW 5 in the clinical setting in patients with functional dyspepsia and irritable bowel syndrome. Gastroenterology 2013; 144 (5, Supp. 1): 682 (Mo1881).
  37. Ottillinger B et al. STW 5 (Iberogast®) - a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65-72.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies